All women have BRCA1 and BRCA2 genes, but only some women have mutations in those genes.

Doctors and scientists are always looking for better ways to care for people with breast cancer. To make scientific advances, doctors design research studies involving volunteers, called clinical trials. In fact, every drug that is now approved by the U.S. Food and Drug Administration (FDA) was tested in clinical trials.

In a study published in Cancer Research, BCRF researchers Drs. Jill Bargonetti and Funmi Olopade report a possible new treatment strategy that targets vulnerabilities in triple-negative breast cancer (TNBC), a particularly aggressive form of the disease with limited treatment options.